15038 studies
OBJECTIVE: This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide appro…
AIM: This study assessed the cost-effectiveness of oral semaglutide versus subcutaneous dulaglutide for type 2 diabetes mellitus (T2DM) from the perspective of the Taiwanese healthcare payer, considering the self-paid status of oral semaglutide and t…
INTRODUCTION: Regulatory reviews in 2023-2024 reignited concern about possible suicidality with Glucagon-like peptide-1 (GLP-1) receptor agonists used for weight management. While clinical trials and real-world studies have not confirmed an increased…
BACKGROUND: To comprehensively evaluate the relative efficacy and safety of lifestyle interventions, pharmacological therapies (orlistat, liraglutide, and semaglutide), and bariatric surgeries [Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG)…
A 49-year-old woman developed new-onset type 1 diabetes after initiating Wegovy (semaglutide) via an online clinic, without prior screening. She experienced rapid weight loss and hyperglycemia symptoms. Blood tests indicated high GAD65 and low C-pept…
OBJECTIVE: Semaglutide shows potential in cardiovascular protection, yet its specific role and mechanism in H/R injury are unclear. Given the role of autophagy in cardiomyocyte protection and the unclear mechanism of semaglutide in H/R - induced inju…
BACKGROUND: User experience has a significant impact on pharmaceutical drug effectiveness. Social media platforms like X (formerly Twitter) have become prominent spaces where individuals share their medication-related experiences, especially with wid…
The obesity epidemic is a major health burden that enhances susceptibility to a broad spectrum of metabolic-associated comorbidities, ranging from fatty liver disease and endocrine dysfunction to traditional risks like type 2 diabetes mellitus and ca…
AIMS/HYPOTHESIS: Initial dose-escalation has been shown to mitigate gastrointestinal adverse events in people treated with incretin-based medications. We aimed to analyse dose-response relationships for the proportion of study participants reporting…
Individuals who carry two copies of the apolipoprotein E ε4 (ε4) allele are at high risk of developing Alzheimer's disease (AD), yet the effects ofε4 homozygosity on biological pathways related to AD over the lifespan are unknown. Here we analyzed th…
BACKGROUND AND AIMS: The glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide has demonstrated efficacy for the secondary prevention of cardiovascular disease among patients with overweight/obesity without diabetes mellitus. However, the c…
: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use has ignited a debate regarding lo…
BACKGROUND: Rare sugar D-Allulose, a zero-calorie sweetener, markedly ameliorates obesity. It reportedly stimulates the release of endogenous glucagon-like peptide 1 (GLP-1) to activate vagal afferent and directly influences the neurons in hypothalam…
Obesity in women over 65 represents a growing clinical challenge, particularly due to its association with increased risks of cardiovascular disease, osteoarthritis, frailty, sleep-breathing disorders, and sarcopenia. The prevalence of obesity in thi…
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has demonstrated metabolic and weight benefits in diabetic and obese patients with chronic kidney disease (CKD) who are not on dialysis; however, evidence in the hemodialysis (H…
IMPORTANCE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of therapeutics approved to treat chronic conditions such as cardiovascular disease, diabetes, and/or obesity. However, whether GLP-1 RAs' efficacy varies by age, sex…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are newer medications used to treat type 2 diabetes mellitus (T2DM) and obesity. There is growing evidence of a potential association between the use of GLP-1 RAs and non-arteritic anterior ischem…